Trial HIV vaccine passes key test

Trial HIV vaccine passes key test

"The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection", he added.

Previous attempts at HIV vaccines have been limited to specific strains of the virus found in certain parts of the world.

A vaccine is a vital weapon in the war against the virus, which infects an 1.8 million people each year.

Vaccine caused the correct reaction of the immune system all 393 participants. The aim is to trigger immune responses against a wide variety of HIV strains, according to authors of the study published Friday in The Lancet medical journal. At present around 37 million individuals are living with HIV/AIDS with 1.8 million new infections and 1 million deaths annually says the World Health Organization. Light of science has tested the drug on healthy people with great attention to detail for the most accurate result, in which identified potential side effects, the safety of the drug and the desired dosage. Both groups were also given an injection of the common cold virus to boost their immune systems - once at the start of the trial and again 12 weeks in.

While the researchers say these results are a step in the right direction, a new round of testing must occur to prove the drug is effective in staving off the disease in humans.

Their trial of vaccine included the 400 healthy people and then their next level of study is going to include 2,600 women of South Africa which are said to be at risk of Infection of HIV.

Indeed, the NHP 13-19 study of 72 rhesus monkeys assigned one of five vaccine regimens or placebo found that Ad26/Ad26 plus gp140 not only induced similar types of immune responses in humans, but 67% protection against acquisition of SHIV (two-sided Fisher's exact test P=0.007).

Hazard to go up against adopted France of his hero Zidane
France's Kylian Mbappe (3 goals) is the highest scoring teenager in a World Cup tournament since Pele scored six in 1958. France beat Uruguay with goals either side of half-time from Raphael Varane and Antoine Griezmann .

Nearly 80 million people are estimated to have been infected since the virus was first diagnosed in the early 1980s.

The study used so-called "mosaic" vaccine combinations. The HIV-1 vaccine proved safe and is now set to go to the next phase, which will be conducted in 2600 women in Southern Africa in a trial called imbokodo, a Zulu word for "rock". "We don't know whether protection in monkeys means there will be protection in humans".

These types of trials are created to test out whether an intervention is safe and works at the most basic level.

The co-author of this study, DR. Dan H. Barouch, at the Harvard Medical School, said in a statement, "I would say that we are pleased with these data so far, but we have to interpret the data cautiously". "We eagerly await the results of the phase 2b efficacy trial called HVTN705, or "Imbokodo", which will determine whether or not this vaccine will protect humans against acquiring HIV".

This study was supported by Janssen Vaccines & Prevention BV and the NIH, the Ragon Institute of MGH, MIT and Harvard, and a cooperative agreement between the Henry M Jackson Foundation for the Advancement of Military Medicine and the US Department of Defense.

More than 80% of people who received this version also showed positive signs for 2 other measures of immune response.

Related Articles